Fully automated

platforms

PERSONALIZED IMAGING WITHOUT ADDED WORK IN YOUR WORKFLOW

Imbio is unique in delivering full quantitative analysis and 3D visualization to support personalized diagnosis and care planning, as a fully-automated solution. Imbio platforms provide efficient clinical workflow for physicians and flexible, software-only options for IT teams.

imbio platform graphic

FOR PHYSICIANS

Making breakthrough image analysis viable in daily care means Imbio is committed to providing application which are:

  • FULLY AUTOMATED

    no stand-alone workstations, no user interfaces to learn. Imbio receives image series automatically at completion of a patient scan and returns results without user intervention.

  • ACCESSIBLE

    Imbio inserts analysis outputs (3D DICOM series and quantitative reports) directly into the patient study making them available to anyone, anywhere with PACS access.

  • FIRST-READ READY

    Imbio analysis run in just minutes. Our goals is simple: Imbio results are ready when you are, the first time you review a patient study.



FOR IT TEAMS

Imbio puts our cloud and virtual computing expertise to work for you, offering platform options to meet your technology and institutional policy preferences.

  • IMBIO CLOUD

    offers access to all Imbio analysis with minimal start-up effort and investment. Imbio processing remains fully automated by installing only the Imbio Bridge (cloud connector application) inside your firewall. Bridge provides automated de-identification / re-identification and encrypted transmission of imaging series to and from the Imbio Cloud.


  • IMBIO ENTERPRISE

    is an on premise version of the Imbio platform for customers who prefer a fully in-house solution. Enterprise is a flexible, software-only (VMware) deployment, dynamically scalable based on analysis volume required.


Please Contact Us to learn more about the Imbio fully-automated platforms.

What people are saying

“Given the prevalence and increasing impact of COPD worldwide, there is a crucial need to develop quantitative imaging methodologies which can more objectively characterize the underlying disease phenotypes and ideally, quantify response to therapy.”
BRIAN D. ROSS, PH.D.
Professor of Radiology and Biological Chemistry, Co-Director, Center for Molecular Imaging University of Michigan

“As the practice of Radiology becomes increasingly more competitive, the advantage will go to imaging centers that can provide imaging techniques and imaging biomarkers that answer important clinical questions that cannot be answered by imaging competitors.”
MURRAY A. SOLOMON, MD.
Medical Director, Los Gatos MRI